Assessment of the aggregate index of systemic inflammation in dyslipidemia with dry eye disease: a retrospective case-control - Scorecard - MDSpire

Assessment of the aggregate index of systemic inflammation in dyslipidemia with dry eye disease: a retrospective case-control

  • By

  • Amani Y. Alhalwani

  • Asma Altasan

  • Nawaf Alasmari

  • Asma Almutiri

  • Mustafa Sunbul

  • Razan Khalifa

  • Jumanah Makhtoum

  • Shatha Jambi

  • June 11, 2026

  • 0 min

Share

Clinical Scorecard: Evaluation of Systemic Inflammation Index in Patients with Dyslipidemia and Dry Eye Disease: A Retrospective Case-Control Study

At a Glance

CategoryDetail
ConditionDyslipidemia and Dry Eye Disease
Key MechanismsInflammation assessed via aggregate index of systemic inflammation (AISI) and inflammatory biomarkers like C-reactive protein (CRP).
Target PopulationPatients diagnosed with dyslipidemia, specifically those with and without dry eye disease.
Care SettingOutpatient clinic at King Abdulaziz Medical City, Jeddah, Saudi Arabia.

Key Highlights

  • DLP is prevalent in 43% of the Saudi population.
  • Higher neutrophil and monocyte counts were observed in DLP-DED patients compared to DLP-only patients.
  • AISI positively correlated with CRP and negatively correlated with HDL and total cholesterol.
  • DED is characterized by discomfort, blurred vision, and tear-film instability.
  • Inflammation may act as both a cause and effect in the relationship between DLP and DED.

Guideline-Based Recommendations

Diagnosis

  • Diagnosis of DLP and DED based on clinical assessment.

Management

  • Control lipid levels to prevent and treat DED.

Monitoring & Follow-up

  • Monitor lipid profiles and inflammatory biomarkers in patients with DLP.

Risks

  • Increased levels of triglycerides, LDL cholesterol, and total cholesterol are associated with a higher risk of DED.

Patient & Prescribing Data

Patients with dyslipidemia, with a focus on those also diagnosed with dry eye disease.

Further evaluation of inflammatory biomarkers may improve understanding of DED pathogenesis.

Clinical Best Practices

  • Consider the aggregate index of systemic inflammation (AISI) as a biomarker for systemic inflammation in DLP.
  • Evaluate the correlation between lipid profiles and dry eye disease progression.

Related Resources & Content

Original Source(s)

Related Content